[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nhl---non-hodgkins-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nhl---non-hodgkins-lymphoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100655930","phase-1-sctb35-and-sctb41-with-or-without-chemotherapy-in-non-hodgkin-lymphoma-100655930",false,"NCT07819188","SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma","A Phase Ib\u002FII Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of SCTB35 in Combination With SCTB41, With or Without Concomitant Chemotherapy, in Patients With Non-Hodgkin's Lymphoma.","Inclusion Criteria:\n\n* Aged 18 to 80 years (inclusive) at the time of informed consent\n* Histologically or cytologically confirmed B cell neoplasm.\n* Phase 1: Relapsed or refractory disease after at least two prior systemic therapy.\n* Measurable or evaluable disease at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Adequate organ and bone marrow function\n* Life expectancy of ≥ 3 months\n\nExclusion Criteria:\n\n* Prior treatment with bispecific antibodies targeting both CD20 and CD3\n* Prior treatment with antibodies targeting both PD-1\u002FPD-L1, PD-(L)1\u002FVEGF(R) or PD-(L)1\u002FTGF-β\n* Eligible for high dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT)\n* Known central nervous system (CNS) involvement by lymphoma\n* Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks\n* Chemotherapy and other non-investigational antineoplastic agents within 4 weeks or 5 half-lives (whichever is shorter) prior to first SCTB35 administration","ALL","18 Years","80 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of SCTB35 and SCTB41 With or Without Chemotherapy in non-Hodgkin's lymphoma patients.",[28],"NHL - Non-Hodgkin's Lymphoma","NOT_YET_RECRUITING","2026-09-08",{"date":32,"type":33},"2026-09-14","ACTUAL",{"date":35,"type":21},"2026-09-30",{"date":37,"type":21},"2029-09-30",{"name":39,"class":40},"Sinocelltech Ltd.","INDUSTRY"]